个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Effect of liver and metabolic toxicity on survival and quality of life in patients with high-volume, metastatic hormonesensitive prostate cancer receiving rezvilutamide in the CHART trial

| 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Ye, D.[1] * ; Jiang, S.[2] ; Luo, H.[3] ; Dong, P.[4] ; Wang, Z.[5] ; Xing, N-Z.[6] ; Ma, T.[7] ; Wang, Z.[8] ; Gu, X.[9] ; Zhou, G.[10] ; Xue, X.[11] ; Sun, Z.[12] ; Guo, J.[13] ; Yang, Y.[14] ; Wang, C.[15] ; Shan, G.[16] ; Zhang, A.[17] ; Ding, D.[18] ; Lian, J.[19] ; Wang, W.[19] ;
机构： [1]Fudan Univ, Dept Urol, Shanghai Canc Ctr, Shanghai, Peoples R China [2]Hunan Canc Hosp, Dept Urol, Changsha, Peoples R China [3]Chongqing Univ, Dept Urol, Canc Hosp, Chongqing, Peoples R China [4]Sun Yat Sen Univ, Dept Urol, Canc Ctr, Guangzhou, Peoples R China [5]Nanjing Med Univ, Dept Urol, Jiangsu Prov Hosp, Affiliated Hosp 1, Nanjing, Peoples R China [6]Chinese Acad Med Sci, Dept Urol, Canc Hosp, Beijing, Peoples R China [7]Hebei Univ, Dept Urol, Affiliated Hosp, Baoding, Peoples R China [8]Lanzhou Univ, Dept Urol, Hosp 2, Lanzhou, Peoples R China [9]Jilin Univ, Dept Urol, China Japan Union Hosp, Hosp 3, Changchun, Peoples R China [10]Northern Jiangsu Peoples Hosp, Dept Urol, Yangzhou, Jiangsu, Peoples R China [11]Fujian Med Univ, Dept Urol, Affiliated Hosp 1, Fuzhou, Peoples R China [12]Fudan Univ, Dept Urol, Huadong Hosp, Shanghai, Peoples R China [13]Fudan Univ, Dept Urol, Zhongshan Hosp, Shanghai, Peoples R China [14]Beijing Canc Hosp, Dept Urol, Beijing, Peoples R China [15]Jilin Univ, Dept Urol, Hosp 1, Changchun, Peoples R China [16]Liaoning Canc Hosp & Inst, Dept Urol, Shenyang, Peoples R China [17]Hebei Med Univ, Dept Urol, Hosp 4, Shijiazhuang, Hebei, Peoples R China [18]Henan Prov Peoples Hosp, Dept Urol, Zhengzhou, Peoples R China [19]Jiangsu Hengrui Pharmaceut Co Ltd, Clin Res & Dev, Shanghai, Peoples R China
出处：
DOI： 10.1016/j.annonc.2023.10.387
ISSN：
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Fudan Univ, Dept Urol, Shanghai Canc Ctr, Shanghai, Peoples R China
推荐引用方式(GB/T 7714)：
Ye D.,Jiang S.,Luo H.,et al.Effect of liver and metabolic toxicity on survival and quality of life in patients with high-volume, metastatic hormonesensitive prostate cancer receiving rezvilutamide in the CHART trial[J].ANNALS OF ONCOLOGY.2023,34:S1575-S1575.doi:10.1016/j.annonc.2023.10.387.
APA：
Ye, D.,Jiang, S.,Luo, H.,Dong, P.,Wang, Z....&Wang, W..(2023).Effect of liver and metabolic toxicity on survival and quality of life in patients with high-volume, metastatic hormonesensitive prostate cancer receiving rezvilutamide in the CHART trial.ANNALS OF ONCOLOGY,34,
MLA：
Ye, D.,et al."Effect of liver and metabolic toxicity on survival and quality of life in patients with high-volume, metastatic hormonesensitive prostate cancer receiving rezvilutamide in the CHART trial".ANNALS OF ONCOLOGY 34.(2023):S1575-S1575

资源点击量：15101 今日访问量：3 总访问量：963 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持：重庆聚合科技有限公司 地址：保定市莲池区裕华东路212号